Sterling Capital Management’s Bright Minds Biosciences DRUG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.1K Buy
243
+217
+835% +$15.3K ﹤0.01% 2431
2026
Q2
$1.82K Sell
26
-19
-42% -$1.49K ﹤0.01% 3012
2026
Q1
$3.28K Buy
45
+15
+50% +$1.21K ﹤0.01% 2867
2025
Q4
$2.34K Buy
30
+19
+173% +$1.27K ﹤0.01% 3047
2025
Q3
$667 Hold
11
– – ﹤0.01% 3135
2025
Q2
$287 Buy
+11
New +$330 ﹤0.01% 3211

Other funds holding DRUG

Sterling Capital Management's DRUG Position: Q3 2026 in Review

Sterling Capital Management increased its Bright Minds Biosciences (DRUG) stake by 835% in Q3 2026, buying an estimated $15.3K and bringing the position to 243 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

Sterling Capital Management first reported a position in DRUG in Q2 2025 and has held it in 6 quarters since. 109 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

  • Sterling Capital Management held 243 shares of Bright Minds Biosciences worth $12.1K as of Q3 2026.
  • Sterling Capital Management bought 217 Bright Minds Biosciences shares in Q3 2026, an estimated $15.3K.
  • Bright Minds Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2431 holding.
  • Sterling Capital Management first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 6 quarters since.
  • 109 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.